Organoids refer to tissue analogs with a certain spatial structure formed by in vitro three-dimensional (3D) culture of adult stem cells or pluripotent stem cells, and are one of the fastest-growing research hotspots in the field of stem cells in the past 10 years. In 2022, the FDA passed the Modernization Act 2.0 and approved the world's first new drug (NCT04658472) based entirely on preclinical data obtained from "organoid chip" research to enter clinical trials, which has aroused a lot of attention and heated discussions in the organoid industry. The scientific research results in the field of organoids have been increasing year by year, and China's scientific research strength ranks second in the world. It is predicted that the global 3D cell culture market will reach 16.642 billion yuan in 2028, growing at a CAGR of approximately 14.87%. The global organoid market size is expected to reach RMB 1.9 billion in 2028, with a compound annual growth rate (CAGR) of 18.4%.
In recent years, organoid technology has been integrated into many fields such as medicine, biotechnology and pharmaceuticals, bringing about earth-shaking changes. From simulating simple cell structures to being able to reproduce the complex physiological functions of organs, organoid technology has gradually released its own application value, and its application scenarios have been continuously expanded and enriched. Research on developmental biology and disease modeling, drug screening and R&D, precision medicine, regenerative medicine, organoid chips, and even organoid intelligence, organoid technology presents endless possibilities.
( For more details: Tansi Biology )
Conference Highlights
2- day summit & professional technology exhibition, fully focusing on the field of 3D cell culture organoids
20+ industry leaders share experience insights and application cases
Three summits held concurrently: 3D cell culture organoids + cell and gene therapy + single cell sequencing and precision medicine
80+ high-quality booths display the latest technologies and solutions
Jointly reported by 100+ media, the most influential CGT industry event in the industry
200+ global cell therapy and gene therapy related companies participated
1500+ domestic and foreign participants
Core topics:
Organoid models simulate human diseases
Brain organoid construction and its application in neurological disease research
Aortic degenerative diseases and vascular organ-on-a-chip
Research progress of organoids in human model systems
Multidisciplinary application of organoid chips
3D cell culture solutions
Construction of organoid sample bank (Biobank) Using
organoids to study developmental biology and disease modeling
Personalization of organoid chips and induced pluripotent stem cell technology
Organoid intelligence - "biocomputer" based on organoids
Who should attend?
Colleges, research institutes, hospitals, patients, medical R&D, CRO companies, organoid platforms, organoid culture, organoid storage, organoid-related professional services, medical testing, drug sensitivity testing, new drug development, reagent consumables, equipment, 3D printing, matrix materials, bioreactors...
Part of the previous participating companies
Ruijin Hospital, Tsinghua University, Tongji University School of Medicine, Graduate School of Chinese Academy of Social Sciences, Second Affiliated Hospital of An Medical University, Fudan Institute of Biomedical Sciences, Central China Normal University, Jinan University, Jiangsu University School of Medicine, Wuhan University School of Medicine, Wuhan School of Bioengineering, Xinjiang Medical University, ASC Therapeutics, AstraZeneca, Abbott Biotech, GenScript Biotech, Angpu Biotech, Auscom Biotech, Bangyao Biology, Beihai Kangcheng, Binuozi, Iron Biology, Lakeside Biology, Bona West Asia, Santian Pharmaceutical, Shenglin Bio, Panen Bio, Yuanjian Rica, Fosun Kite, Gaubb Medical Group, Guite Medicine, Sinopharm Jinqi, Kangwanda Pharmaceutical, Qilu Pharmaceutical, Huadao Biology, Huaxia Yuanbio, Huida Biology, Huier Biology, Jiyuan Gene, Kebei Yuanquan, Longxin Biology, Lepu Biology, Longchang Pharmaceutical, Roche, New Phosphate, Nulunjie Biological, Qilu Pharmaceutical, Merck, Ruizheng Pharmaceuticals, Zhizhi Chemical, Sanofi, Sessel Qing, Sanofi Sheng Guojian, 3SBio, 3SBio, Henlius, Hengrun Dasheng, Huicun Medical, Kazhi Bio, Laifu Medical, Longyao Bio, Longyao Bio, Shanghai Cell Therapy Group, Reindeer Bio, Shanghai Pharmaceuticals Group, Innovia, CSPC, Sudi Medicine, Fangde Menda, Xueji Bio, Immophy Bio, Yimofeng Bio, Weisheng Pharmaceutical, Takeda, West Lake Biology, Xingdehan, Xing Yiang, Xueji Bio, Reindeer Bio, Wuming Junuo, Chia Tai Tianqing wait...
Some past speakers
Highlights of previous sessions
